Frankfurt (Germany) (AFP) - The German company Bayer announced that it intends to invest $2.2 billion (1.95 billion euros) in a new pharmaceutical facility in the United States, amid pressure exerted by the administration of US President Donald Trump on pharmaceutical companies to increase manufacturing on American soil.

Published on: 03/10/2026 - 12:42

The group stated that this project in the city of New Albany, Ohio, comes as a continuation of investments worth more than $7 billion that Bayer has made in the areas of research, development and pharmaceutical manufacturing in the United States over the past five years.

Bayer CEO Bill Anderson said in a statement late Friday: “Bayer has long viewed the United States as a major manufacturing base and center for innovation.”

He added, "This important investment confirms our firm commitment."

Trump has imposed customs duties on some patented medicines manufactured abroad, and he also plans to impose duties on imports of generic medicines starting in 2028, in an effort to attract more drug manufacturing operations to the United States.

Companies that pledge to build factories in the United States are expected to be charged lower duties than those that rely on imports.

Bayer, also a leading manufacturer of agricultural chemicals, indicated that the new site would create about 600 “high-value” jobs.

The company also stated that the project will also provide about 1,500 job opportunities in the building and construction sector during the construction phase of the facility.

The site will focus on producing medicines intended to treat cancer, heart and kidney diseases.

The first phase of the facility is expected to begin operating in 2031, followed by the second phase in 2034.

© 2026 AFP

The content you want to browse is no longer in service or is currently unavailable.